Ivonescimab’s Western Survival Signal Strengthens
Summit reported an updated overall-survival hazard ratio of 0.76 for ivonescimab plus chemotherapy in the global Phase 3 HARMONi trial, both in the full population and in Western patients. The Western subgroup improved from…
